Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia

To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • procedure : ablative allogeneic hematopoietic cell transplant
  • procedure : high dose chemotherapy then autologous hematopoietic cell transplant

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - 60 Years

Inclusion Criteria

- adequate organ function - normal bone marrow cytogenetics

External Links

Explore related trials

Contact information

Primary Contact:

BMT Referrals 6507230822

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: